Interleukin-27 as a Novel Therapy for Inflammatory Bowel Disease

A Critical Review of the Literature

Caroline Andrews, Mairi H McLean, Scott K Durum

Research output: Contribution to journalLiterature review

14 Citations (Scopus)
4 Downloads (Pure)

Abstract

Inflammatory bowel disease (IBD) is an inflammatory disorder of the intestine that affects an estimated 329 per 100,000 people in the United States and is increasing in incidence within a number of cultures worldwide. Likely due to its incompletely understood pathophysiology and etiology, the standard treatments for IBD are only efficacious in subsets of patients and often do not induce lasting remission. As a result, novel therapies are needed. The success of anti-tumor necrosis factor-α treatment in a subset of patients with IBD demonstrated that therapy targeting a single cytokine could be efficacious in IBD, and clinical trials investigating the blockade of a variety of cytokines have commenced. Interleukin (IL) 27 is a relatively recently discovered type I cytokine with established roles in infectious disease, autoimmunity, and cancer in a variety of organs. IL-27 was identified as a candidate gene for IBD, and a number of studies in mouse models of IBD have demonstrated that IL-27 therapy is protective. However, in contrast to these investigations, genetic deletion of the IL-27 receptor has been shown to be protective in some mouse models of IBD. The purpose of this review is to highlight the recent literature investigating the role of IL-27 in IBD and to discuss the possible explanations for the sometimes conflicting results of these studies. Evidence supporting IL-27 therapy as a treatment for IBD will also be discussed.

Original languageEnglish
Pages (from-to)2255-2264
Number of pages10
JournalInflammatory Bowel Diseases
Volume22
Issue number9
Early online date26 May 2016
DOIs
Publication statusPublished - Sep 2016

Fingerprint

Interleukin-27
Inflammatory Bowel Diseases
Therapeutics
Cytokines
Interleukin Receptors
Autoimmunity
Intestines
Communicable Diseases
Tumor Necrosis Factor-alpha
Clinical Trials

Keywords

  • Crohn’s disease
  • IBD
  • IL-27
  • ulcerative colitis

Cite this

Interleukin-27 as a Novel Therapy for Inflammatory Bowel Disease : A Critical Review of the Literature. / Andrews, Caroline; McLean, Mairi H; Durum, Scott K.

In: Inflammatory Bowel Diseases, Vol. 22, No. 9, 09.2016, p. 2255-2264.

Research output: Contribution to journalLiterature review

@article{a551219ee2814d9ea32596bef969d91f,
title = "Interleukin-27 as a Novel Therapy for Inflammatory Bowel Disease: A Critical Review of the Literature",
abstract = "Inflammatory bowel disease (IBD) is an inflammatory disorder of the intestine that affects an estimated 329 per 100,000 people in the United States and is increasing in incidence within a number of cultures worldwide. Likely due to its incompletely understood pathophysiology and etiology, the standard treatments for IBD are only efficacious in subsets of patients and often do not induce lasting remission. As a result, novel therapies are needed. The success of anti-tumor necrosis factor-α treatment in a subset of patients with IBD demonstrated that therapy targeting a single cytokine could be efficacious in IBD, and clinical trials investigating the blockade of a variety of cytokines have commenced. Interleukin (IL) 27 is a relatively recently discovered type I cytokine with established roles in infectious disease, autoimmunity, and cancer in a variety of organs. IL-27 was identified as a candidate gene for IBD, and a number of studies in mouse models of IBD have demonstrated that IL-27 therapy is protective. However, in contrast to these investigations, genetic deletion of the IL-27 receptor has been shown to be protective in some mouse models of IBD. The purpose of this review is to highlight the recent literature investigating the role of IL-27 in IBD and to discuss the possible explanations for the sometimes conflicting results of these studies. Evidence supporting IL-27 therapy as a treatment for IBD will also be discussed.",
keywords = "Crohn’s disease, IBD, IL-27, ulcerative colitis",
author = "Caroline Andrews and McLean, {Mairi H} and Durum, {Scott K}",
note = "Conflicts of interest and source of funding: Drs Andrews and Durum are supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute. The authors have no conflicts of interest to disclose.",
year = "2016",
month = "9",
doi = "10.1097/MIB.0000000000000818",
language = "English",
volume = "22",
pages = "2255--2264",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Interleukin-27 as a Novel Therapy for Inflammatory Bowel Disease

T2 - A Critical Review of the Literature

AU - Andrews, Caroline

AU - McLean, Mairi H

AU - Durum, Scott K

N1 - Conflicts of interest and source of funding: Drs Andrews and Durum are supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute. The authors have no conflicts of interest to disclose.

PY - 2016/9

Y1 - 2016/9

N2 - Inflammatory bowel disease (IBD) is an inflammatory disorder of the intestine that affects an estimated 329 per 100,000 people in the United States and is increasing in incidence within a number of cultures worldwide. Likely due to its incompletely understood pathophysiology and etiology, the standard treatments for IBD are only efficacious in subsets of patients and often do not induce lasting remission. As a result, novel therapies are needed. The success of anti-tumor necrosis factor-α treatment in a subset of patients with IBD demonstrated that therapy targeting a single cytokine could be efficacious in IBD, and clinical trials investigating the blockade of a variety of cytokines have commenced. Interleukin (IL) 27 is a relatively recently discovered type I cytokine with established roles in infectious disease, autoimmunity, and cancer in a variety of organs. IL-27 was identified as a candidate gene for IBD, and a number of studies in mouse models of IBD have demonstrated that IL-27 therapy is protective. However, in contrast to these investigations, genetic deletion of the IL-27 receptor has been shown to be protective in some mouse models of IBD. The purpose of this review is to highlight the recent literature investigating the role of IL-27 in IBD and to discuss the possible explanations for the sometimes conflicting results of these studies. Evidence supporting IL-27 therapy as a treatment for IBD will also be discussed.

AB - Inflammatory bowel disease (IBD) is an inflammatory disorder of the intestine that affects an estimated 329 per 100,000 people in the United States and is increasing in incidence within a number of cultures worldwide. Likely due to its incompletely understood pathophysiology and etiology, the standard treatments for IBD are only efficacious in subsets of patients and often do not induce lasting remission. As a result, novel therapies are needed. The success of anti-tumor necrosis factor-α treatment in a subset of patients with IBD demonstrated that therapy targeting a single cytokine could be efficacious in IBD, and clinical trials investigating the blockade of a variety of cytokines have commenced. Interleukin (IL) 27 is a relatively recently discovered type I cytokine with established roles in infectious disease, autoimmunity, and cancer in a variety of organs. IL-27 was identified as a candidate gene for IBD, and a number of studies in mouse models of IBD have demonstrated that IL-27 therapy is protective. However, in contrast to these investigations, genetic deletion of the IL-27 receptor has been shown to be protective in some mouse models of IBD. The purpose of this review is to highlight the recent literature investigating the role of IL-27 in IBD and to discuss the possible explanations for the sometimes conflicting results of these studies. Evidence supporting IL-27 therapy as a treatment for IBD will also be discussed.

KW - Crohn’s disease

KW - IBD

KW - IL-27

KW - ulcerative colitis

U2 - 10.1097/MIB.0000000000000818

DO - 10.1097/MIB.0000000000000818

M3 - Literature review

VL - 22

SP - 2255

EP - 2264

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 9

ER -